EAM Investors’s Profound Medical PROF Stock Holding History

EAM Investors’s Portfolio PROF Stock Details PROF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-10,330	Closed	-$208K	–	399
2021 Q1	$208K	Sell	10,330 -42,233	-80%	-$1.01M	0.03%	322
2020 Q4	$1.08M	Buy	+52,563	New	+$967K	0.18%	256
2020 Q2	–	Sell	-63,602	Closed	-$605K	–	312
2020 Q1	$605K	Buy	+63,602	New	+$825K	0.19%	187

Other funds holding PROF

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

LBA

Letko, Brosseau & Associates Montreal, Quebec, Canada $6.2B AUM 38.92% 1-Year Est. Return

Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

Blackcrane Capital Bellevue, Washington $16.3M AUM 19.53% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

Gagnon Advisors New York $136M AUM 21.55% 1-Year Est. Return

EAM Investors's PROF Position: Q2 2021 in Review

EAM Investors sold out of Profound Medical (PROF) in Q2 2021, closing a stake of 10,330 shares — an estimated $208K sold.

EAM Investors first reported a position in PROF in Q1 2020 and held it in 3 quarters. The position peaked at $1.08M in Q4 2020. 48 funds tracked by Wall St. Rank hold PROF as of Q2 2021.

EAM Investors reported no remaining Profound Medical position as of Q2 2021 after selling out during the quarter.
EAM Investors sold 10,330 Profound Medical shares in Q2 2021, an estimated $208K.
EAM Investors first reported a position in Profound Medical in Q1 2020 and held it in 3 quarters.
EAM Investors's Profound Medical position peaked at $1.08M in Q4 2020.
48 funds tracked by Wall St. Rank held Profound Medical as of Q2 2021.

Based on EAM Investors's 13F filing for Q2 2021, filed 13 Aug 2021.